CD79A and pertussis: Nasal pertussis vaccines, such as BPZE1, which contains a genetically inactivated strain of B. pertussis, are under development to offer dual benefits: protection against the disease and prevention of nasal colonization by inducing B. pertussis-specific mucosal secretory IgA responses [87,88].